MIPLYFFA Shows 5-Year Disease Stability in Niemann-Pick Type C Treatment Study
Zevra Therapeutics (NASDAQ:ZVRA) announced the presentation of four posters at…
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
Zevra Therapeutics CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the…
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a…